In Vivo High-Throughput Screening Approaches

In vivo high throughput screening has emerged as a critical bridge between cell-based assay data and the complex pharmacological environment of the whole organism, addressing a recognized bottleneck in translational drug discovery. Conventional in vitro screening campaigns routinely generate large panels of active compounds, yet the majority fail when tested in animal models or clinical trials due to inadequate pharmacokinetics, unanticipated off-target toxicity, or failure to engage the target in a physiological context. By incorporating whole-organism screening earlier in the discovery cascade, researchers can obtain systemic ADME (absorption, distribution, metabolism, and excretion), toxicological, and efficacy data simultaneously from a single in vivo experiment.¹

The demand for scalable in vivo screening models has spurred the development of platforms based on lower vertebrates and invertebrates — most prominently the zebrafish (Danio rerio) and the nematode Caenorhabditis elegans — that offer throughput characteristics approaching those of cell-based assays while retaining key biological complexities absent from monolayer cultures. These whole-organism drug screening platforms are now applied across oncology, neuroscience, infectious disease, and rare disease research, complementing and, in some cases, partially replacing early rodent studies in integrated translational pharmacology workflows.²

Why in vivo screening models outperform cell-based assays for translational pharmacology

The fundamental limitation of in vitro drug screening is its inability to capture the systemic factors that determine compound behavior in living organisms. Cells cultured on plastic or within hydrogels are deprived of circulating immune cells, neuroendocrine signaling, vascular transport, and the metabolic contributions of liver, gut, and kidney — all of which influence whether a drug reaches its target at a therapeutic concentration, how long it persists in the body, and what off-target organs it affects. These omissions explain why compounds that demonstrate nanomolar potency and excellent selectivity in cell-based assays frequently fail at the point of in vivo testing.

In vivo high throughput screening models restore these systemic variables within a tractable experimental format. Lower organisms such as zebrafish larvae and C. elegans share substantial genetic conservation with humans, maintain functional analogues of key organ systems, and can be dosed by compound immersion, circumventing the injection procedures required for mammalian models. The result is a phenotypic readout that integrates bioavailability, target engagement, and systemic tolerability in a single experiment — information that no in vitro assay, however sophisticated, can provide.³

Zebrafish screening: a vertebrate model for high-throughput in vivo pharmacology

The zebrafish has become the most widely used vertebrate organism for whole-organism drug screening, owing to a combination of biological and practical advantages that are difficult to replicate in other in vivo systems. Zebrafish embryos and larvae are small enough to be housed individually in the wells of 96- or 384-well plates, are optically transparent during early development allowing fluorescence-based imaging of internal organs in real time, and develop rapidly — reaching a stage with functional cardiovascular, nervous, and gastrointestinal systems within 120 hours of fertilization. Each adult female produces hundreds of eggs per clutch, providing the biological material necessary for large-scale compound screens.²

The zebrafish genome has been fully sequenced, revealing that approximately 71% of human protein-coding genes have at least one zebrafish orthologue, and 82% of known human disease genes have a zebrafish counterpart.³ This genetic conservation underpins the capacity of zebrafish to model a wide range of human pathologies, including epilepsy, cardiomyopathy, leukemia, and metabolic disorders. Compounds can be added directly to the water in which larvae are immersed, enabling passive uptake across the permeable larval skin and gill epithelia — a simple exposure route that is compatible with liquid handling automation and multi-compound matrix screening designs.

Table 1. Comparison of whole-organism in vivo screening platforms by throughput, key advantages, and primary limitations.

C. elegans as a model for quantitative high-throughput in vivo screening

The nematode Caenorhabditis elegans has a longer history in pharmacological research than zebrafish and was the first multicellular organism to have its genome fully sequenced. Its adult body length of approximately 1 mm, three-day life cycle from egg to reproductive adult, and near-complete optical transparency make it highly compatible with automated imaging workflows. C. elegans can be cultured in liquid media in 384- and 1536-well plate formats, enabling quantitative high-throughput screening (qHTS) campaigns with full concentration-response characterization across tens of thousands of compounds.¹

The worm's approximately 60% genetic homology with humans — covering many genes implicated in neurodegeneration, metabolism, and ageing — has supported the development of C. elegans disease models for conditions including Parkinson's disease, Alzheimer's disease, type 2 diabetes, and amyotrophic lateral sclerosis (ALS). Drug candidates identified through C. elegans phenotypic screens have advanced into preclinical development, validating the platform's utility as a first-pass in vivo filter for compound libraries. Limitations include the absence of a circulatory system and many mammalian organ types, which restrict the range of disease processes that can be accurately modelled.

Automation, imaging, and data analysis in whole-organism screening

The adaptation of whole-organism screening to high-throughput formats has required substantial advances in automated imaging, image analysis, and data management. Standard fluorescence and brightfield microscopes are insufficient for the volumetric complexity of whole organisms at the speeds required for large library screens. High-content imaging platforms equipped with automated z-stack acquisition and confocal optics are capable of capturing three-dimensional fluorescence data from zebrafish larvae or C. elegans in multi-well format at the throughput needed for library-scale campaigns. Machine learning-based image segmentation algorithms have been developed to extract quantitative phenotypic data from these images, measuring endpoints such as heart rate, body length, fluorescent reporter intensity, neuronal morphology, and tumor volume in xenograft models.⁴

Liquid handling automation is equally critical. Robotic dispensing systems capable of accurately transferring nanoliter to microliter volumes into multi-well plates containing live organisms must accommodate the biological variability of whole animals — particularly the tendency of C. elegans to aggregate at pipette tips and the photo-sensitivity of certain zebrafish phenotypes. Integrated workflows combining automated compound dispensing, incubation, high-content imaging, and phenotypic data extraction now allow in vivo screening campaigns to approach the throughput of cell-based assays at a fraction of the cost of mammalian studies.

Translational pharmacology and the role of mammalian in vivo screening

Despite the utility of invertebrate and lower vertebrate models, mammalian in vivo systems remain indispensable in translational pharmacology for the definitive assessment of pharmacokinetics, target engagement, and safety in the context most predictive of human biology. Mouse models — including syngeneic tumor models, patient-derived xenografts (PDX), and genetically engineered mouse models (GEMMs) — provide the pharmacological complexity necessary to evaluate immune-mediated drug responses, drug–drug interactions, and dose-schedule optimization. Their inherently low throughput, however, precludes their use in primary library screens.⁵

The emerging paradigm in integrated in vivo screening is a tiered approach in which C. elegans or zebrafish screens filter large compound libraries for activity and tolerable toxicity, with confirmed hits then progressed to more resource-intensive rodent pharmacology studies. This funnel strategy significantly reduces the number of compounds tested in mammals, lowering cost, improving animal welfare outcomes, and concentrating in-depth mechanistic and pharmacokinetic characterization on the most promising candidates. The development of predictive translational pharmacology models that quantitatively link pharmacodynamic observations in lower organisms to expected human exposures represents an active and important area of research.⁶

Advancing Biomarker Discovery With Liquid Biopsy Research

This webinar explores how liquid biopsy research is advancing biomarker discovery through extracellular vesicle (EV)-associated biomarkers and circulating tumor DNA (ctDNA).
View Webinar

Advertisement

Key application areas for in vivo high throughput screening currently include:

• Oncology: zebrafish xenograft models for real-time imaging of tumor growth inhibition and drug combination screening
• Neuroscience: C. elegans and zebrafish larval behavior assays for CNS-active compound identification and seizure liability assessment
• Infectious disease: whole-organism infection models in zebrafish for antimicrobial and antifungal compound evaluation in the context of host immune responses
• Rare and metabolic diseases: C. elegans genetic disease models for phenotypic rescue screening against human disease gene orthologues
• Cardiotoxicity: zebrafish cardiac assays for early identification of QT interval prolongation and structural cardiac liabilities

Outlook for in vivo high-throughput screening in drug discovery

The integration of in vivo high throughput screening into mainstream drug discovery workflows is accelerating, driven by improvements in automated imaging, miniaturized whole-organism assay formats, and the growing recognition that earlier access to in vivo data reduces late-stage attrition. The development of humanized zebrafish and C. elegans strains — engineered to express human disease-relevant genes or carrying patient-derived mutations — is expanding the translational validity of these platforms beyond their natural biological scope.

Convergence with artificial intelligence-based phenotypic analysis, multi-omics profiling of whole-organism drug responses, and the application of CRISPR-based gene editing to create isogenic disease models are expected to further increase the predictive value of in vivo screening systems. As the pharmaceutical industry continues to seek strategies that reduce clinical failure rates and improve the efficiency of preclinical pharmacology, whole-organism screening platforms are positioned to play a growing and increasingly integrated role in the translation of molecular hits into viable drug candidates.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.